Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of flavanonol natural products

A drug, the technology of silibinin, which is applied in the field of medicinal use of natural products of dihydroflavonols, can solve the problems such as the elaboration of the therapeutic effect of NASH

Inactive Publication Date: 2019-10-29
CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] At present, there are many studies on the protective effect of silibinin on the liver, but the exact therapeutic effect on NASH has not been elaborated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of flavanonol natural products
  • Pharmaceutical use of flavanonol natural products

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] 1 Grouping of experimental animals

[0021] After single-cage adaptation and gavage adaptation, the animals were divided into 9 groups according to their body weight and food consumption. The mice were adapted for one week, and the mice in groups 2-8 began to be fed with MCD feed. Co-feeding induced 6 weeks, while the normal group Feed mice with normal chow.

[0022] 2 Construction of NASH animal model

[0023] The NASH model induced by a methionine-choline-deficient (MCD) diet was adopted, and MCD is an animal model widely recognized internationally.

[0024] 8-week-old male mice, weighing 18-22g. The body weight of the animals was weighed before the start of MCD modeling. Two weeks after modeling, blood was taken to test serum TG, TC, ALT and AST, and liver was taken to test TG and TC. The NAS pathological score of the model group was greater than 5 points, indicating that the NASH model was successfully constructed. The mice were fed with MCD for 6 weeks.

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a flavanonol compound, namely silibinin, to treatment of a metabolic disease, namely non-alcoholic steatohepatitis (NASH).

Description

technical field [0001] The invention relates to the use of a dihydroflavonol compound silibinin in treating non-alcoholic steatohepatitis (Non-alcoholic steatohepatitis, NASH), a metabolic disease. Background technique [0002] The present invention relates to the application of silibinin component in treating metabolic disease non-alcoholic steatohepatitis (Non-alcoholic steatohepatitis, NASH). [0003] Silybin {3,5,7-trihydroxy-2-(3-(3-hydroxy-4-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo [b][1,4]-dioxin-6-yl (dioxin-6-yl)chroman-4-one; or according to the European Pharmacopoeia (Ph.Eur.) called (2R,3R)- 3,5,7-Trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1 , 4-Benzo-dioxin-6-yl]-2,3-dihydro-4H-1-benzopyran-4-one} is the main constituent of silymarin and is derived from milk thistle (Silybum marianum ( The main flavonoid compounds extracted from SilybummarianumGaertneri)). [0004] The structure of silybin is shown below: [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/357A61P1/16
CPCA61K31/357A61P1/16
Inventor 姬建新
Owner CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com